Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response

the advent of hybrid positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (MRI) scanners resulted in an increased clinical relevance of nuclear medicine in oncology. the use of [18F]-fluorodeoxyglucose ([18F]FDG) has also made it possible to study tumors (including breast cancer) from not only a dimensional perspective but also from a metabolic point of view. In particular, the use of [18F]FDG PET allowed early confirmation of the efficacy or failure of therapy. the purpose of this review was to assess the literature concerning the response to various therapies for different subtypes of breast cancer through PET. we start by summarizing studies that investigate the validation of PET/CT for the assessment of the response to therapy in breast cancer; then, we present studies that compare PET imaging (including PET devices dedicated to the breast) with CT and MRI, focusing on the identification of the most useful parameters obtainable from PET/CT. we also focus on novel non-FDG radiotracers, as they allow for the acquisition of information on specific aspects of the new therapies.